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http://www.molecularpain.com/content/8/1/78RESEARCH Open AccessTrigeminal-Rostral Ventromedial Medulla circuitry
is involved in orofacial hyperalgesia contralateral
to tissue injury
Bryan Chai1,2, Wei Guo1,2, Feng Wei1,2, Ronald Dubner1,2 and Ke Ren1,2*Abstract
Background: Our previous studies have shown that complete Freund’s adjuvant (CFA)-induced masseter
inflammation and microinjection of the pro-inflammatory cytokine interleukin-1β (IL-1β) into the subnucleus
interpolaris/subnucleus caudalis transition zone of the spinal trigeminal nucleus (Vi/Vc) can induce contralateral
orofacial hyperalgesia in rat models. We have also shown that contralateral hyperalgesia is attenuated with a lesion
of the rostral ventromedial medulla (RVM), a critical site of descending pain modulation. Here we investigated the
involvement of the RVM-Vi/Vc circuitry in mediating contralateral orofacial hyperalgesia after an injection of CFA
into the masseter muscle.
Results: Microinjection of the IL-1 receptor antagonist (5 nmol, n=6) into the ipsilateral Vi/Vc attenuated the
CFA-induced contralateral hyperalgesia but not the ipsilateral hyperalgesia. Intra-RVM post-treatment injection of
the NK1 receptor antagonists, RP67580 (0.5-11.4 nmol) and L-733,060 (0.5-11.4 nmol), attenuated CFA-induced
bilateral hyperalgesia and IL-1β induced bilateral hyperalgesia. Serotonin depletion in RVM neurons prior to
intra-masseter CFA injection prevented the development of contralateral hyperalgesia 1–3 days after CFA injection.
Inhibition of 5-HT3 receptors in the contralateral Vi/Vc with direct microinjection of the select 5-HT3 receptor
antagonist, Y-25130 (2.6-12.9 nmol), attenuated CFA-induced contralateral hyperalgesia. Lesions to the ipsilateral Vc
prevented the development of ipsilateral hyperalgesia but did not prevent the development of contralateral
hyperalgesia.
Conclusions: These results suggest that the development of CFA-induced contralateral orofacial hyperalgesia is
mediated through descending facilitatory mechanisms of the RVM-Vi/Vc circuitry.
Keywords: Pain, Descending modulation, Serotonin, Substance P, IL-1β, Vi/Vc transition zone, RatBackground
Orofacial muscle pain is a debilitating disorder that
diminishes the quality of life and seriously inhibits the
health of the patient by impairing a person’s ability to
eat and drink. Trigeminal pain also spreads to wide oro-
facial areas and is a serious clinical problem. Reports
have shown that patients with unilateral myofascial tem-
poromandibular muscle and joint disorders (TMD) ex-
perience bilateral hyperalgesia [1,2]. Very little research
has focused on the possible circuitry and mechanisms* Correspondence: kren@umaryland.edu
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reproduction in any medium, provided the orinvolved in the development of contralateral orofacial
hyperalgesia after deep tissue orofacial injury.
Traditionally, orofacial pain research has focused on
the activation of the subnucleus caudalis (Vc) of the
spinal trigeminal nucleus (STN) [3-7]. Despite the em-
phasis of orofacial pain research in the Vc, the subnu-
cleus interpolaris/subnucleus caudalis transition zone
(Vi/Vc) of the STN has been more recently shown to be
involved in mechanisms of deep tissue trigeminal pain
[8-11]. We have shown that complete Freund’s adjuvant
(CFA)-induced masseter inflammation and intra-Vi/Vc
microinjection of the pro-inflammatory cytokine,
interleukin-1β (IL-1β), induce contralateral orofacial
hyperalgesia in rat [12,13]. However, contralateral hyper-
algesia is not seen with intra-Vc IL-1β microinjection.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chai et al. Molecular Pain 2012, 8:78 Page 2 of 12
http://www.molecularpain.com/content/8/1/78Similar to the behavioral findings, our previous stud-
ies showed that CFA-induced masseter inflammation
results in bilateral expression of Fos protein in the
Vi/Vc and ipsilateral expression of Fos protein in the
Vc [14].
We have also shown that IL-1β-induced contralateral
hyperalgesia is attenuated with ibotenic acid lesions in
the rostral ventromedial medulla (RVM), a midline site
that is critical in descending pain modulation [12]. Our
previous studies have shown that bilateral reciprocal
connections exist from the Vi/Vc to the RVM [14]. This
suggests that activation of RVM neurons may be neces-
sary for the development of contralateral hyperalgesia.
Immunohistochemical localization shows moderate
amounts of the substance P receptor, neurokinin-1 re-
ceptor (NK1-R), in the RVM [15-17]. Research
has shown that Substance P activation of NK1-R in
the RVM is involved in descending facilitation of pain
[18-25]. We have also shown that the serotonin system
is involved in descending facilitation in the spinal
cord after tissue and nerve injury [26]. Furthermore,
spinal 5-HT3 receptor activation has been shown to con-
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Figure 1 Inhibition of IL-1R in the ipsilateral Vi/Vc attenuates contrala
by IL-1R inhibition in the ipsilateral Vi/Vc. A, B. Post-treatment: CFA (0.05 m
prior to IL-1ra microinjection into the ipsilateral Vi/Vc (0.5μl). C, D. Pre-treatm
masseter muscle 15 min after IL-1ra microinjection into the ipsilateral Vi/Vc
CFA-induced contralateral hyperalgesia as compared to saline treated rats.
saline. *: p<0.05; **: p<0.01; ***: p<0.001 (ANOVA with repeated measures aBased on these studies of descending facilitation and
behavioral hyperalgesia at the spinal and trigeminal
levels, we propose that the activation of the NK1-R in
the RVM by input from the ipsilateral Vi/Vc results in
enhanced release of 5-HT from descending RVM-Vi/Vc
neurons. Activation of 5-HT3 receptors in the contralat-
eral Vi/Vc ultimately leads to contralateral hyperalgesia.
Results
Contralateral orofacial hyperalgesia is mediated via IL-1R
activation in the ipsilateral Vi/Vc
Our previous studies have shown that CFA injection into
the masseter muscle and IL-1β injections into the Vi/Vc
transition zone generate bilateral mechanical hyperalge-
sia as seen by the significant decreases in EF50 values
[12,13]. To test whether activation of IL-1 receptors (IL-
1R) in the Vi/Vc is involved in CFA-induced contralat-
eral hyperalgesia, an IL-1R antagonist (IL-1ra) was
injected. Microinjection of IL-1ra (5 nmol, n=6) into the
ipsilateral Vi/Vc 24 h after CFA treatment attenuated
contralateral hyperalgesia 1 h after microinjection as
compared to saline-treated rats (Figure 1A). Intra-Vi/Vc
pretreatment of IL-1ra (5 nmol, n=6) also attenuated
CFA-induced contralateral hyperalgesia compared toB
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l; 1:1 oil/saline) was injected unilaterally into the masseter muscle 24 h
ent: CFA (0.05 ml; 1:1 oil/saline) was injected unilaterally into the
(0.5 μl). Pre-treatment and post-treatment of IL-1ra attenuated
IL-1ra did not attenuate ipsilateral hyperalgesia. *: IL-1ra (5 nmol) vs
nd Student Neuman-Keuls post-hoc test).
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Pre-treatment and post-treatment of IL-1ra did not at-
tenuate ipsilateral hyperalgesia (Figure 1B, D). These
results suggest that IL-1R in the ipsilateral Vi/Vc is
involved in CFA-induced contralateral orofacial hyper-
algesia but not the ipsilateral orofacial hyperalgesia.
NK1-R activation in the RVM is critical to the
development of bilateral orofacial hyperalgesia
Previously we showed that intra-Vi/Vc IL-1β-induced
contralateral orofacial hyperalgesia was mediated via
RVM neurons [12]. The RVM is a midline structure that
lacks laterality and projects neurons bilaterally to the
ventral Vi/Vc [14]. NK1-R activation in the RVM has
been shown to contribute to capsaicin-induced hyper-
algesia [22]. Similarly, we showed that NK1-R activation
in the RVM is involved in mediating behavioral hyper-
algesia after hindpaw inflammation [24]. To test whether
NK1-R activation in the RVM was involved in orofacial
contralateral hyperalgesia, two NK1-R antagonists,
RP67580 and L-733,060 were microinjected into the
RVM. RP67580 attenuated CFA-induced bilateral hyper-
algesia in a dose-dependent manner. Attenuation of
hyperalgesia was seen 0.5-5 h post-injection with the
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Figure 2 Inhibition of NK1-R in the RVM attenuates inflammatory bila
attenuates CFA-induced bilateral hyperalgesia. CFA (0.05 ml; 1:1 oil/saline) w
RP67580 (A, B) and L-733,060 (C, D) microinjection into the RVM (0.5 μl). +:
saline. +,#,*: p<0.05; ++,##,**: p<0.01; +++,###,***: p<0.001 (ANOVA with recontralateral side (Figure 2A) and ipsilateral side
(Figure 2B). Similar results were observed using the
NK1-R antagonist L-733,060 (Figure 2C, D).
Inhibition of NK1-R activation in the RVM also atte-
nuated IL-1β (160 fmol) – induced bilateral orofacial
hyperalgesia. Microinjection of RP67580 and L-733,060
into the RVM 15 min after IL-1β injection into the Vi/
Vc resulted in a dose-dependent attenuation of bilateral
hyperalgesia. Application of RP67580 (11.4 nmol; n=5)
resulted in attenuation of hyperalgesia 0.5-4 h post-
injection on the contralateral side (Figure 3A) and
ipsilateral side (Figure 3B). Similar results were observed
using NK1-R antagonist L-733,060 (Figure 3C, D).
These results suggest that contralateral and ipsilateral
orofacial hyperalgesia are mediated by NK1-R activation
in the RVM.
5-HT depletion in the RVM inhibits the development of
CFA-induced contralateral orofacial hyperalgesia
The results suggest that NK1-R activation of RVM neu-
rons may lead to descending facilitation of pain on the
contralateral side and ipsilateral side. We previously
showed that depletion of 5-HT in the RVM neurons
inhibits injury-induced hyperalgesia [26] and an intra-
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Figure 3 Inhibition of NK1-R in the RVM attenuates IL-1β-induced bilateral hyperalgesia. Intra-RVM microinjection of NK1-R antagonists
attenuates intra-Vi/Vc IL-1β-induced bilateral hyperalgesia. IL-1β (160 fmol/0.5 μl) was microinjected unilaterally into the Vi/Vc 15 min prior to
RP67580 (A, B) and L-733,060 (C, D) microinjection into the RVM (0.5 μl). +: lowest dose vs. saline. #: middle dose vs. saline. *: highest dose vs.
saline. +,#,*: p<0.05; ++,##,**: p<0.01; +++,###,***: p<0.001 (ANOVA with repeated measures and Student Neuman-Keuls post-hoc test).
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pothesis that NK1-R activation in the RVM could ultim-
ately result in 5-HT-dependent descending facilitation to
the contralateral Vi/Vc. To evaluate the role of 5-HT in
the development of contralateral orofacial hyperalgesia,
down regulation of tryptophan hydroxylase-2 (Tph-2), a
rate limiting enzyme for 5-HT synthesis in RVM neu-
rons was achieved by RNA interference. Since the RVM
is a midline structure that projects bilaterally, RNA
interference would result in bilateral 5-HT depletion at
the Vi/Vc. In CFA-induced hyperalgesic rats, western
blot showed that Tph-2 expression in the RVM was sig-
nificantly down regulated at 4–8 days after Tph-2
shRNA administration when compared to control (n=4;
p<0.001) (Figure 4A). Immunostaining at 4 days after
shRNA administration shows a reduction of 5-HT
immunoreactivity in the ventral Vi/Vc axons of CFA-
induced hyperalgesic rats when compared to control
shRNA (Figure 4B, C). 5-HT depletion inhibits the de-
velopment of CFA-induced contralateral orofacial hyper-
algesia 4–6 days after CFA injection (Figure 4D).
However, 5-HT depletion did not inhibit development of
ipsilateral hyperalgesia after CFA masseter muscle injec-
tion (Figure 4E). These data suggests that 5-HT-
dependent descending facilitation of pain is necessaryfor the development of contralateral hyperalgesia but
not the ipsilateral hyperalgesia.
Vi/Vc 5-HT3 receptor activation is necessary for CFA-
induced contralateral orofacial hyperalgesia
Previous studies have shown that 5-HT3 receptor ex-
pression is upregulated in the spinal cord and trigeminal
nuclei in animal models of persistent pain [29,30]. In
similar models of persistent pain, hyperalgesia is attenu-
ated following 5-HT3 receptor inhibition [28,29,31]. To
test whether the 5-HT3 receptor was involved in contra-
lateral orofacial hyperalgesia, a 5-HT3 receptor antagon-
ist, Y-25130 was microinjected into the contralateral Vi/
Vc following CFA masseter muscle injection. Contralat-
eral orofacial hyperalgesia was dose-dependently attenu-
ated following Y-25130 (n=6) (Figure 5A). In contrast,
Y-25130 microinjected into the contralateral Vi/Vc did
not attenuate the ipsilateral hyperalgesia (Figure 5B).
Microinjection of Y-25130 into the ipsilateral Vi/Vc did
not attenuate either ipsilateral or contralateral hyper-
algesia (Figure 5C, D). These results suggest that 5-HT3
receptor activation in the contralateral Vi/Vc facilitates
the CFA-induced contralateral hyperalgesia but may
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Figure 4 5-HT depletion in the RVM prevents the development of contralateral hyperalgesia. RNAi of Tph-2 in the RVM prevents the
development of CFA-induced contralateral hyperalgesia. A. Western blot analysis of Tph-2 in the RVM. CFA (0.05 ml; 1:1 oil/saline) injected
unilaterally into the masseter muscle 3 days after shRNA administration. Tph-2 protein expression was measured in rats at 4 day (n=4), 6 days
(n=4) and 8 days (n=4) after shRNA was administered. Tph-2 protein expression was measured in rats given control shRNA (n=4) 4 days after the
shRNA was administered. B, C. Immunohistochemical fluorescent staining of 5-HT in the Vi/Vc of shRNA treated rats (n=3) 24 h after CFA
administration shows decreased 5-HT expression in the Vi/Vc following Tph-2 depletion in rats as compared to control shRNA (n=3). CFA was
administered 3 days after shRNA administration. (Ba: control shRNA, 10x; Bb: control shRNA,40x. Ca: Tph-2 shRNA,10x; Cb: Tph-2 shRNA,40x). D, E.
Mechanical hyperalgesia was tested in 5-HT depleted rats with CFA-induced hyperalgesia. Control or Tph-2 shRNA was administered and CFA
was injected 3 days after. Mechanical hyperalgesia was inhibited in 5-HT depleted rats as compared to control on the contralateral side (D), but
not the ipsilateral side (E). *: CFA + Tph-2 shRNA vs. CFA + control shRNA, p<0.05; **: p<0.01; ***: p<0.001 (ANOVA with repeated measures and
Student Neuman-Keuls post-hoc test).
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CFA-induced ipsilateral orofacial hyperalgesia
The present data provide evidence that Vi/Vc was ne-
cessary for contralateral orofacial hyperalgesia. Our
present data also showed that injection of IL-1ra into
the Vi/Vc did not affect the ipsilateral hyperalgesia.Our previous studies have shown that afferent nocicep-
tive input into the Vc is critical for the development of
ipsilateral hyperalgesia but does not affect contralateral
hyperalgesia [13]. This suggests that the ipsilateral and
contralateral hyperalgesia may be transmitted through











CFA + saline (n=6)
CFA + Y-25130 (12.9 nmol) (n=6)
CFA + Y-25130 (6.5 nmol) (n=6)








Time post drug (h)











Time post drug (h)
pre 1.0 3.0 4.0 5.02.0pre
CFA Y-25130
Contralateral
CFA + saline (n=5)









Time post drug (h)











Time post drug (h)





Figure 5 Vi/Vc 5-HT3 receptor inhibition attenuates contralateral hyperalgesia. Inhibition of the 5-HT3 receptor in the contralateral Vi/Vc
attenuates CFA-induced contralateral hyperalgesia. CFA (0.05 ml; 1:1 oil/saline) was injected into the masseter muscle and 24 h later, Y-25130 was
microinjected (0.5 μl) into the contralateral Vi/Vc (A, B). Y-25130 microinjection into the contralateral Vi/Vc attenuated contralateral hyperalgesia
(A) but not ipsilateral hyperalgesia (B). Y-25130 microinjection into the ipsilateral Vi/Vc (C, D) did not attenuate ipsilateral or contralateral
hyperalgesia. +: lowest dose vs. saline. #: middle dose vs. saline. *: highest dose vs. saline. +,#,*: p<0.05; ++,##,**: p<0.01; +++,###,***: p<0.001
(ANOVA with repeated measures and Student Neuman-Keuls post-hoc test).
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of the excitotoxin, ibotenic acid. Ibotenic acid induces
glutamate-mediated toxicity to neuron cell bodies
through activation of glutamate receptors. An ipsilat-
eral Vc lesion prior to CFA injection inhibited the de-
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Figure 6 Vc activation is necessary for the development of ipsilateral
the master muscle prevents the development of ipsilateral hyperalgesia. Ib
between vertebrae C1-C2, 7 days prior to ipsilateral CFA injection into the
development of contralateral hyperalgesia (A). However, lesion of the ipsila
*: Ibotenic Acid (6.3 nmol) vs. saline, p<0.05; **: p<0.01; ***: p<0.001 (ANOVdid not inhibit contralateral hyperalgesia development
(Figure 6A). This suggests that ipsilateral Vc input is
primarily involved in the development of ipsilateral
hyperalgesia while Vi/Vc input is necessary for the de-
















hyperalgesia. Lesion of the ipsilateral Vc prior to CFA injection into
otenic Acid (6.3 nmol) was administered to unilaterally to the Vc
masseter muscle. Lesion of the ipsilateral Vc did not prevent the
teral Vc did prevent the development of ipsilateral hyperalgesia (B).
A with repeated measures and Student Neuman-Keuls post-hoc test).
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and Vi/Vc transition zone
Animals were perfused with 4% paraformaldehyde at
the conclusion of the experiment and the sections of
brain stem tissues were stained with cresyl violet for
histological verification of the sites of injection in the
Vi/Vc, RVM, and Vc (Figure 7A, B, C). Animals with
missed sites of injection showed no significant effect



















Figure 7 Histological representation of injection sites within the RVM
within the RVM (A), the Vi/Vc transition zone (B), and Vc (C). Diagrams are
RP67580; Vi/Vc: IL-1β. IL-1ra, and Y-25130; Vc: ibotenic acid. Closed circles re
circles represent cannula tips placed outside the site of interest. Dashed cir
involved dorsal mandibular and middle maxillary divisions. Animals with m
control and were excluded from experimental groups. CN 7: facial nerve; sp
nucleus.Discussion
Our previous studies have shown that CFA-induced mas-
seter inflammation and intra-Vi/Vc microinjection of IL-1β
result in contralateral orofacial hyperalgesia [12,13]. We have
also shown that lesions in the RVM prevented the develop-
ment of contralateral hyperalgesia [12]. The present study
further shows that the development of contralateral orofacial
hyperalgesia involves IL-1R activation in the ipsilateral Vi/Vc
that ultimately leads to NK1-R activation in the RVM and










and Vi/Vc. Histological representation of the cannula tip placement
separated according to the drug administered. RVM: L-733,060 and
present cannula tips accurately placed within the site of interest. Open
cles represent affected area from ibotenic acid injection, which
issed sites of injection showed no significant effect compared to
5: Spinal trigeminal nucleus; Py; pyramidal tract; LRt: lateral reticulate
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http://www.molecularpain.com/content/8/1/78The RVM is a critical site in descending modulation of
pain [32,33]. Much research has focused on the descend-
ing inhibitory affects of the opioid system within the
RVM [34,35]. Our lab has shown that upregulation and
phosphorylation of AMPA receptors in the RVM can
lead to descending inhibition of inflammatory pain
[36,37]. However, there has been mounting evidence of
RVM-mediated descending facilitation [38-42]. The
RVM has been shown to have reciprocal connections
with trigeminal neurons in the Vi/Vc transition zone
[14]. Our previous studies indicated that intra-masseter
muscle CFA injection and intra-Vi/Vc IL-1β injection
produces bilateral orofacial hyperalgesia. The RVM was
previously shown to mediate the IL-1β-induced hyper-
algesia on the contralateral side [12].
The contralateral effect was also produced by an IL-1β
injection into the Vi/Vc but was not produced after IL-
1β injection into the Vc [13]. Rats with masseter muscle
inflammation exhibit increased IL-1β expression in Vi/
Vc astroglia [43]. Furthermore, IL-1 receptor (IL-1R) ac-
tivation induces a protein kinase-C dependent signaling
cascade that leads to N-methyl-D-aspartate receptor
phosphorylation and ultimately behavioral hyperalgesia
[43]. In our present study, inhibition of IL-1R activa-
tion in the ipsilateral Vi/Vc before CFA treatment pre-
vented the development of contralateral orofacial
hyperalgesia. Similarly, inhibition of IL-1R activation in
the ipsilateral Vi/Vc after CFA treatment resulted in
an attenuation of the contralateral hyperalgesia. These
results support the view that activation of IL-1R in the
ipsilateral Vi/Vc is involved in the development and
maintenance of deep tissue orofacial pain on the
contralateral site.
Substance P has been shown to be involved in RVM
descending modulation of pain [22,25]. NK1-R activa-
tion in the RVM enhances excitatory glutamatergic
inputs to RVM neurons in rats with persistent pain
[44]. NK1-R antagonism in the RVM attenuated CFA-
induced thermal hyperalgesia in the hind paw [23].
Our previous studies have shown that NK1-R expres-
sion is increased in the RVM following hind paw in-
flammation and direct injection of substance P into
the RVM can induce bilateral thermal hyperalgesia in
the hind paw [24]. We also showed that Substance
P-induced hyperalgesia can be mediated by 5-HT,
NMDA, and GABAA circuits [24]. We have now
shown that NK1-R inhibition in the RVM attenuated
inflammatory orofacial hyperalgesia bilaterally. These
results suggest that NK1-R activation in the RVM con-
tributes to descending facilitation that mediates inflam-
matory orofacial hyperalgesia to the ipsilateral and
contralateral side.
In the spinal cord, administration of a 5-HT3 receptor
antagonist inhibits evoked responses of dorsal hornneurons after noxious stimulation [29] and intra-RVM
cholecystokinin-induced mechanical and thermal hyper-
algesia [45]. Similarly, intrathecal administration of a 5-
HT3 receptor antagonist attenuates formalin-induced
hind paw flinching and spinal ERK activation [46]. We
have previously shown that after the depletion of en-
dogenous 5-HT while maintaining the viability and func-
tion of serotonergic neurons, descending facilitation is
dependent on the activation of serotonergic neurons in
the RVM [26]. The present study shows that descending
serotonergic facilitation is necessary for the development
and maintenance of contralateral orofacial hyperalgesia
after CFA-induced masseter inflammation. Furthermore,
activation of Vi/Vc 5-HT3 receptors is necessary for in-
duction of the CFA-induced contralateral orofacial
hyperalgesia to develop.
Interestingly, our results show that IL-1R inhibition
and 5-HT3 receptor blockade in the ipsilateral Vi/Vc
does not affect ipsilateral hyperalgesia. This finding sug-
gests that Vc activation from afferent input is important
for the ipsilateral hyperalgesia while the development of
contralateral hyperalgesia requires Vi/Vc-RVM circuitry.
Supporting this hypothesis, lesions of the Vc inhibited
the development of ipsilateral hyperalgesia without
affecting contralateral hyperalgesia. It appears that the
afferent drive into the Vc is the primary mechanism
involved in ipsilateral hyperalgesia consistent with our
previous findings [13].
A puzzling observation from this study is that shRNA
treatment of Tph-2 in the RVM, which down regulates
5-HT bilaterally, did not affect ipsilateral hyperalgesia.
One would expect that hyperalgesia would be attenuated
bilaterally. One possible explanation is that ipsilateral
hyperalgesia is dominated by hyperexcitability and cen-
tral sensitization in the Vc driven by peripheral input
which masks the loss of descending facilitation. An alter-
native explanation is that the absence of attenuation of
ipsilateral hyperalgesia may be related to the finding of
varying degrees of descending inhibitory and facilitatory
input into the contralateral and ipsilateral medullary/
spinal dorsal horn. It has been shown that descending
pain modulation is in dynamic balance between inhibi-
tory and facilitatory signals [47]. After hind paw inflam-
mation, there is a time-dependent enhancement of
descending inhibition on the ipsilateral side [48,49]. Des-
cending 5-HT projections from the RVM also produce
dual inhibitory and facilitatory effects due to activation
of different 5-HT receptor subtypes [50]. The net effect
of descending modulation may be facilitatory on the
contralateral side and inhibitory on the ipsilateral side in
this masseter inflammation model. Thus, depletion of
descending 5-HT on the ipsilateral side would reduce
predominant inhibitory signals and the hyperalgesia
would be sustained.
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Overall, our results support the hypothesis that the Vi/
Vc–RVM circuitry mediates the development of hyper-
algesia on the contralateral side after ipsilateral deep tissue
injury. CFA-induced inflammatory orofacial hyperalgesia
produces an increase in IL-1β activation of IL-1R in the
ipsilateral Vi/Vc. IL-1R activation in the Vi/Vc ultimately
leads to NK1-R activation in the RVM. This leads to acti-
vation of descending serotonin-containing RVM neurons
that project to the Vi/Vc bilaterally. Activation of 5-HT3
receptors in the contralateral Vi/Vc results in deep tissue
orofacial pain in the contralateral masseter muscle
(Figure 8). The findings further suggest that descending
facilitatory mechanisms may also contribute to the de-




Male Sprague–Dawley rats (n=222 total) weighing 200-
300g (Harlan) were used for all experiments. Female rats
were excluded to avoid complications of the estrous
cycle. Rats were provided food and water ad libitum on
a 12-h light/dark schedule. The experiments were
approved by the Institutional Animal Care and Use
Committee at the University of Maryland Dental School.
Surgical preparation/cannulation
Rats were anesthetized using 50 mg/kg of pentobarbital
sodium (i.p) and 2-3% isoflurane inhalation in a 30/70%
oxygen/nitrogen gas mixture. Rats were placed in a










Figure 8 Vi/Vc-RVM circuitry is necessary for the development of con
development of contralateral orofacial hyperalgesia following unilateral dee
inflammation leads to increased IL-1β activation of IL-1R in the ipsilateral V
leads to descending serotonergic facilitation of pain to the contralateral Vi/
contralateral orofacial hyperalgesia.midline incision was made in the scalp after debride-
ment and sterilization of the surgical field with iodine
wash. For administration of drugs via microinjection,
guide cannulae (C315G, 26 gauge, Plastics One, Roa-
noke, VA) were implanted and cemented into the skull.
A midline opening was made in the skull using a dental
drill and a guide cannula was lowered into the ventral
Vi/Vc transition zone or RVM by referring to the rat
brain atlas [51]. The RVM is termed for the collective
structures that consist of the midline nucleus raphe
magnus (NRM) and the adjacent gigantocellular reticular
nucleus pars α (NGC α). The guide cannula was then
secured with cranioplastic cement. The wounds were
cleaned with antiseptic solution and closed with 4–0 silk
sutures. Animals were allowed to recover for 1 week be-
fore further experimentation. A group of rats received
unilateral intra-masseter muscle injections of the inflam-
matory agent, complete Freund’s adjuvant (CFA, 0.05ml;
1:1 oil/saline). Twenty-four hours later, drugs were
injected into the ventral Vi/Vc transition zone or RVM
through a 33-gauge injection cannula (C315I, Plastic
One) inserted through the tip of the guide cannula. The
injection cannula was connected to a 1-μl Hamilton syr-
inge by polyethylene-10 tubing. All injections (0.5 μl)
were performed by delivering drug or vehicle solutions
slowly over a 2-min period. Recombinant rat IL-1β, IL-1
receptor antagonist (PeproTech; Rocky Hill, NJ) and 5-
HT3 receptor antagonist Y-25130 (Tocris Bioscience;
Ellisville, MO) were microinjected into the Vi/Vc transi-
tion zone. The Neurokinin-1 receptor antagonists L-
733,060 and RP67580 (Tocris Bioscience; Ellisville, MO)













tralateral hyperalgesia. The proposed pathway involved in the
p tissue inflammatory hyperalgesia. Unilateral CFA masseter
i/Vc. Direct or indirect activation of the RVM through NK1-R activation
Vc. Activation of 5-HT3 receptors in the contralateral Vi/Vc leads to
Chai et al. Molecular Pain 2012, 8:78 Page 10 of 12
http://www.molecularpain.com/content/8/1/78antagonist, Y-25130, and L-733,060 were reconstituted
in deionized water while RP67580 was reconstituted in
DMSO.
shRNA
shRNA plasmids containing the 5-HT synthesizing en-
zyme Tryptophan Hydroxylase – 2 (Tph-2) or a
scrambled sequence control was administered into the
RVM with a 1-μL Hamilton syringe (0.5 μg/0.5 μl) over
5 min. Fifteen minutes after the injection, the syringe
was slowly removed and a pair of Teflon-coated silver
positive and negative electrodes spaced 3 mm apart were
placed in a rostrocaudal direction at the injection site
for electroporation (7 square-wave pulses; 50 ms, 40 V, 1
Hz). The rats were allowed to heal for 3 days before uni-
lateral masseter injection of CFA. Behavioral tests were
performed 24 h post-CFA.
Western blot
Naïve and treated rats were anesthetized with 50mg/kg
pentobarbital sodium (i.p) and decapitated. The RVM
tissue was removed as previously described [44]. The
RVM tissue was homogenized and centrifuged at 20,200
x g for 10 min at 4°C, and the supernatant was removed.
The protein concentration was determined. Each sam-
ple contained proteins from one animal. The proteins
(50 μg) were separated on a 7.5% SDS-PAGE gel and
blotted to a nitrocellulose membrane (GE Healthcare
Biosciences, Pittsburgh, PA). The blot was incubated
with rabbit anti-Tph-2 antibody overnight at 4°C. The
membrane was washed with TBS and incubated for 1 h
with anti-goat IgG horseradish peroxidase (HRP)
(1:3000; Santa Cruz Biotechnology, Santa Cruz, CA) in
5% milk/TBS. The immunoreactivity was detected using
enhanced chemiluminescence (ECL) (GE Healthcare,
Pittsburgh, PA). The loading and blotting of equal
amount of proteins were verified by reprobing the mem-
brane with anti-β-actin antiserum (Sigma, St. Louis,
MO). The ECL-exposed films were digitized, and densi-
tometric quantification of immunoreactive bands was
performed using UN-SCAN-IT gel (version 4.3, Silk Sci-
entific). Photoshop software was utilized to construct
the figure from the raw western blot data.
Immunohistochemistry
Rats were anesthetized at various time points after gene
transfer with 50mg/kg of pentobarbital sodium (i.p) and
perfused transcardially with 0.9% saline solution fol-
lowed by 4% paraformaldehyde in 0.1M phosphate buf-
fer solution. The brainstem and cervical spinal cord (C1-
C2) was removed and immersed in the same fixative
overnight at 4°C and transferred to 30% sucrose (w/v) in
0.1 M phosphate buffer solution for cryoprotection.
After several days, 30 μm thick coronal sections of thetissue sample were sectioned with a cryostat at −20°C.
Free floating tissue sections of the Vi/Vc were incubated
with rabbit anti-5-HT (1:4000, Immunostar, Hudson,WI)
antibody overnight at room temperature. After serial
washes, the sections were incubated with Cy2-
conjugated goat anti-rabbit IgG (1:500, Jackson Immu-
noResearch, West Grove, PA). Control staining proced-
ure was performed by omission of the primary antibody.
Photoshop software was utilized to construct the figure
from the original microscope photos.
Vc lesion
Vc lesions were made using 1 μg/0.5 μl of ibotenic acid
injected into the Vc unilaterally [14]. Rats were anesthe-
tized and a 1-μl Hamilton syringe was placed between
C1-C2 vertebrae and ibotenic acid was injected into the
ipsilateral Vc over a 2-min period. The rats were allowed
to heal over 5–7 days. CFA was injected into the ipsilat-
eral side and behavioral testing was performed after 24
h. Ibotenic acid was reconstituted using deionized water.
CFA and behavioral testing
Behavioral tests were conducted under blind conditions
as described elsewhere [52]. A series of calibrated von
Frey filaments were applied to the skin above the mas-
seter muscle. Filaments were applied to the masseter
muscle in increasing forces. Each von Frey filament was
applied 5 times at intervals of a few seconds. A positive
response was regarded as an active withdrawal of the
head from the probing filament. The response frequen-
cies [(number of responses/number of stimuli) X100%]
to a range of von Frey filament forces were determined
and a stimulus–response (S-R) curve plotted. After a
non-linear regression analysis (GraphPad Prism), an
EF50 value, defined as the von Frey filament force (g)
that produces a 50% response frequency, was derived
from the S-R curve. We used EF50 values as a measure
of mechanical sensitivity. A leftward shift of the S-R
curve, resulting in a reduction of EF50, occurred after in-
flammation [14]. This shift of the curve suggests the
presence of mechanical hyperalgesia and allodynia since
there was an increase in response to suprathreshold
stimuli and a decreased response threshold for nocifen-
sive behavior. Data are presented as mean ± S.E.M. Stat-
istical comparisons were made by two-way ANOVA and
ANOVA with repeated measures and post hoc compari-
sons (Neuman-Keuls). P<0.05 was considered significant.
Abbreviations
TMD: Temporomandibular joint disorder; CFA: Complete Freund’s adjuvant;
STN: Spinal trigeminal nucleus; Vc: Subnucleus caudalis of the STN;
Vi/Vc: Subnucleus caudalis/subnucleus interpolaris transition zone of the
spinal trigeminal nucleus; RVM: Rostral ventromedial medulla; EF50: The
effective force that produces 50% response frequency; IL-1β: Interleukin-1β;
IL-1R: Interleukin-1 receptor; IL-1ra: Interleukin-1 receptor antagonist;
Chai et al. Molecular Pain 2012, 8:78 Page 11 of 12
http://www.molecularpain.com/content/8/1/78NK1-R: Neurokinin-1 receptor; Tph-2: Tryptophan hydroxylase-2; i.
p: intraperitoneal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BC was involved in carrying out the behavioral, pharmacological, RNAi,
immunostaining, and histological studies. BC was also involved in the
experimental design and drafted the manuscript. WG was involved in the
experimental design and RNAi and Western blot studies. FW contributed to
the experimental design and the RNAi and immunostaining experiments. KR
and RD conceived the study, participated in its design and coordination, and
helped to draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by National Institute of Health, DE021942, DE11964,
and DE0212804.
Received: 25 July 2012 Accepted: 16 October 2012
Published: 23 October 2012
References
1. Fernández-de-Las-Peñas C, Galan-del-Rio F, Fernandez-Carnero J, Pesquera J,
Arendt-Nielsen L, Svensson P: Bilateral widespread mechanical pain
sensitivity in women with myofascial temporomandibular disorder:
evidence of impairment in central nociceptive processing. J Pain 2009,
10:1170–1178.
2. Fernández-de-Las-Peñas C, Galan-del-Rio F, Ortega-Santiago R, Jimenez-
Garcia R, Arendt-Nielsen L, Svensson P: Bilateral thermal hyperalgesia in
trigeminal and extra-trigeminal regions in patients with myofascial
temporomandibular disorders. Exp Brain Res 2010, 202:171–179.
3. Dubner R, Bennett GJ: Spinal and trigeminal mechanisms of nociception.
Annu Rev Neurosci 1983, 6:381–418.
4. Sessle BJ: Acute and chronic craniofacial pain: brainstem mechanisms of
nociceptive transmission and neuroplasticity, and their clinical correlates.
Crit Rev Oral Biol Med 2000, 11:57–91.
5. Dubner R, Ren K: Brainstem mechanisms of persistent pain following
injury. J Orofacial Pain 2004, 18:299–305.
6. Tashiro A, Okamoto K, Bereiter DA: Chronic inflammation and estradiol
interact through MAPK activation to affect TMJ nociceptive processing
by trigeminal caudalis neurons. Neuroscience 2009, 164(4):1813.
7. Miyamoto M, Tsuboi Y, Takamiya K, Huganir R, Kondo M, Shinoda M, Oi Y,
Iwata K: Involvement of GluR2 and GluR3 subunit C-termini in the
trigeminal spinal subnucleus caudalis and C1-C2 neurons in trigeminal
neuropathic pain. Neurosci Lett 2011, 491(1):8–12.
8. Imbe H, Dubner R, Ren K: Masseteric inflammation-induced fos protein
expression in the trigeminal interpolaris/caudalis transition zone:
Contribution of somatosensory-vagal-adrenal integration. Brain Res 1999,
845:165–175.
9. Zhou Q, Imbe H, Dubner R, Ren K: Persistent fos protein expression after
orofacial deep or cutaneous tissue inflammation in rats: Implications for
persistent orofacial pain. J Comp Neurol 1999, 412:276–291.
10. Ro JY, Harriott A, Crouse U, Capra NF: Innocuous jaw movements increase
c-fos expression in trigeminal sensory nuclei produced by masseter
muscle inflammation. Pain 2003, 104:539–548.
11. Ren K, Dubner R: The role of trigeminal interpolaris-caudalis transition
zone in persistent orofacial pain. Int Rev Neurobiol 2011, 97:207–225.
12. Shimizu K, Chai B, LaGraize SC, Wei F, Dubner R, Ren K: Microinjection of IL-
1beta into the trigeminal transition zone produces bilateral NMDA
receptor dependent orofacial hyperalgesia involving descending
circuitry. Open Pain J 2009, 2:76–83.
13. Shimizu K, Guo W, Wang H, Zou S, LaGraize SC, Iwata K, Dubner R, Ren K:
Differential involvement of trigeminal transition zone and laminated
subnucleus caudalis in orofacial deep and cutaneous hyperalgesia: the
effects of interleukin-10 and glial inhibitors. Mol Pain 2009, 5:75.
14. Sugiyo S, Takemura M, Dubner R, Ren K: Trigeminal transition zone/rostral
ventromedial medulla connections and facilitation of orofacial
hyperalgesia after masseter inflammation in rats. J Comp Neurol 2005,
493:510–523.15. Maeno H, Kiyama H, Tohyama M: Distribution of the substance P receptor
(NK-1 receptor) in the central nervous system. Brain Res Mol Brain Res
1993, 18:43–58.
16. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N:
Immunohistochemical localization of substance P receptor in the central
nervous system of the adult rat. J Comp Neurol 1994, 347:249–274.
17. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC: Autoradiographic
distribution of tachykinin NK2 binding sites in the rat brain: comparison
with NK1 and NK3 binding sites. Neuroscience 2000, 116:761–773.
18. Schafer MK, Nohr D, Krause JE, Weihe E: Inflammation-induced
upregulation of NK1 receptor mRNA in dorsal horn neurones.
Neuroreport 1993, 4:1007–1010.
19. McCarson KE, Krause JE: NK-1 and NK-3 type tachykinin receptor mRNA
expression in the rat spinal cord dorsal horn is increased during
adjuvant or formalin-induced nociception. J Neurosci 1994, 14:712–720.
20. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Superficial
NK1-expressing neurons control spinal excitability through activation of
descending pathways. Nat Neurosci 2002, 5:1319–1326.
21. Budai D, Khasabov SG, Mantyh PW, Simone DA: NK-1 receptors modulate
the excitability of ON cells in the rostral ventromedial medulla. J
Neurophysiol 2007, 97:1388–1395.
22. Pacharinsak C, Khasabov SG, Beitz AJ, Simone DA: NK-1 receptors in the
rostral ventromedial medulla contribute to hyperalgesia produced by
intraplantar injection of capsaicin. Pain 2008, 139:34–46.
23. Hamity MV, White SR, Hammond DL: Effects of neurokinin-1 receptor
agonism and antagonism in the rostral ventromedial medulla of rats
with acute or persistent inflammatory nociception. Neuroscience 2010,
165:902–913.
24. LaGraize SC, Guo W, Yang K, Wei F, Ren K, Dubner R: NK-1 tachykinin
receptors in the rostral ventromedial medulla mediate descending
facilitation of inflammatory hyperalgesia linked to 5-HT3, NMDA and
GABAA receptor dependent spinal circuitry. Neuroscience 2010, 71
(4):1341–1356.
25. Brink TS, Pacharinsak C, Khasabov SG, Beitz AJ, Simone DA: Differential
modulation of neurons in the rostral ventromedial medulla by neurokin-
1 receptors. J Neurophysiol 2012, 107(4):1210–1221.
26. Wei F, Dubner R, Zou S, Ren K, Bai G, Wei D, Guo W: Molecular depletion
of descending serotonin unmasks its novel facilitatory role in the
development of persistent pain. J Neurosci 2010, 30:8624–8636.
27. Chen Y, Oatway MA, Weaver LC: Blockade of the 5-HT3 receptor for days
causes sustained relief from mechanical allodynia following spinal cord
injury. J Neuro Res 2008, 87(2):418–424.
28. Oatway MA, Chen Y, Weaver LC: The 5-HT3 receptor facilitates mechanical
allodynia following spinal cord injury. Pain 2004, 110:259–268.
29. Rahman W, Suzuki R, Webber M, Hunt SP, Dickenson AH: Depletion of
endogenous spinal 5-HT attenuates the behavioural hypersensitivity to
mechanical and cooling stimuli induced by spinal nerve ligation. Pain
2006, 123:264–274.
30. Doucet E, Latrémolière A, Darmon M, Hamon M, Emerit MB:
Immunolabelling of the 5-HT 3B receptor subunit in the central and
peripheral nervous systems in rodents. Eur J Neurosci 2007, 26:355–366.
31. Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW,
Stucky CL, Julius D, Basbaum AI: The 5-HT3 subtype of serotonin receptor
contributes to nociceptive processing via a novel subset of myelinated
and unmyelinated nociceptors. J Neurosci 2002, 22:1010–1019.
32. Mayer DJ, Wolfle TL, Akil H, Carder B, Liebeskind JC: Analgesia from
electrical stimulation in the brainstem of the rat. Science 1971, 174
(4016):1351–1354.
33. Fields HL, Heinricher MM, Mason P: Neurotransmitters in nociceptive
modulatory circuits. Annu Rev Neurosci 1991, 14:219–245.
34. Fang FG, Haws CM, Drasner K, Williamson A, Fields HL: Opioid peptides
(DAGO-enkephalin, dynorphin A(1–13), BAM 22P) microinjected into the
rat brainstem: comparison of their antinociceptive effect and their effect
on neuronal firing in the rostral ventromedial medulla. Brain Res 1989,
501(1):116–128.
35. Boyer JS, Morgan MM, Craft RM: Microinjection of morphine into the
rostral ventromedial medulla produces greater antinociception in male
compared to female rats. Brain Res 1998, 796(1–2):315–318.
36. Guan Y, Guo W, Zou SP, Dubner R, Ren K: Inflammation-induced
upregulation of AMPA receptor subunit expression in brain stem pain
modulatory circuitry. Pain 2003, 104(1–2):401–413.
Chai et al. Molecular Pain 2012, 8:78 Page 12 of 12
http://www.molecularpain.com/content/8/1/7837. Guan Y, Guo W, Robbins MT, Dubner R, Ren K: Changes in AMPA receptor
phosphorylation in the rostral ventromedial medulla after inflammatory
hyperalgesia in rats. Neurosci Lett 2004, 366(2):201–205.
38. Wiertelak EP, Roemer B, Maier SF, Watkins LR: Comparison of the effects of
nucleus tractus solitarius and ventral medial medulla lesions on illness-
induced and subcutaneous formalin induced hyperalgesias. Brain Res
1997, 748:143–150.
39. Urban MO, Gebhart GF: Supraspinal contributions to hyperalgesia. Proc
Natl Acad Sci U S A 1999, 96:7687–7692.
40. Ren K, Dubner R: Descending modulation in persistent pain: an update.
Pain 2002, 100(1–2):1–6.
41. Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary
descending facilitation. Trends Neurosci 2002, 25(6):319–325.
42. Heinricher MM, Tavares I, Leith JL, Lumb BM: Descending control of
nociception: specificity, recruitment and plasticity. Brain Res Rev 2009,
60:214–225.
43. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, Wei F, Dubner
R, Ren K: Glial-cytokine-neuronal interactions underlying the mechanisms
of persistent pain. J Neurosci 2007, 27:6006–6018.
44. Zhang L, Hammond DL: Substance P enhances excitatory transmission on
spinally projecting neurons in the rostral ventromedial medulla after
inflammatory injury. J Neurophysiol 2009, 102(2):1139–1151.
45. Dogrul A, Ossipov MH, Porreca F: Differential mediation of descending
pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors.
Brain Res 2009, 1280:52–59.
46. Svensson CI, Tran TK, Fitzsimmons B, Yaksh TL, Hua XY: Descending
serotonergic facilitation of spinal ERK activation and pain behavior. FEBS
Lett 2006, 580:6629–6634.
47. Vanegas H, Schaible H-G: Descending control of persistent pain: inhibitory
or facilitatory? Brain Res Rev 2004, 46:295–309.
48. Ren K, Dubner R: Enhanced descending modulation of nociception in
rats with persistent hindpaw inflammation. J Neurophysiol 1996, 76:3025–
3037.
49. Terayama R, Guan Y, Dubner R, Ren K: Activity-induced plasticity in brain
stem pain modulatory circuitry after inflammation. Neuroreport 2000,
11:1915–1919.
50. Bardin L: The complex role of serotonin and 5-HT receptors in chronic
pain. Behav Pharmacol 2011, 22(5–6):390–404.
51. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. 5th edition.
Amsterdam: Elsevier; 2005.
52. Ren K: An improved method for assessing mechanical allodynia in the
rat. Physiol Behav 1999, 67:711–716.
doi:10.1186/1744-8069-8-78
Cite this article as: Chai et al.: Trigeminal-Rostral Ventromedial Medulla
circuitry is involved in orofacial hyperalgesia contralateral to tissue
injury. Molecular Pain 2012 8:78.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
